One could make a case for any of the items on your list except #4. Phase-2b and phase-3 trials in ACS are very expensive; MNTA will not conduct such a trial on its own dime, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”